Enterin

Developer of pharmaceuticals that repair the gut-brain axis to treat patient suffering from neurodegenerative diseases

placePhiladelphia, Pennsylvania, United States calendar_todayFounded 2016 groups21 employees language enterininc.com

Registered entities

Innovation

31 patent families (7 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 1,385 times.

YearFilings
20121
20196
202017
202113
202210
20237
20245
20253
20261

Investor mix

2 investors on record; lead investors include Scientia Ventures.

Investor typeCountShare
Venture capital150%
Private equity150%
Coming soon